Home › Companies › CRVO

Pipeline (4 active programs)

Discontinued (1)

• neflamapimod — Stroke · enrollment ended — strategic deprioritization

Capital (as filed)

Cash

$6.1M cash and cash equivalents · Sep 30, 2026 (10-Q)

Short-term investments

$13.5M Sep 30, 2026

Operating cash flow

−$5.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$24.9M cash, runway Q3 2027 per the update of Oct 29, 2026 — the company's own words as read there, not the filed figure

Offering documents (3)

• 2026-07-10 424B3 · Resale (selling stockholders)
• 2026-07-06 S-3 · Shelf registration
• 2026-06-22 424B5 · Priced offering 2.50M shares · at $4.00 · $10.0M gross · 5.7% below the prior close ($4.24, Jun 18, 2026)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (17)

• 2026-11-07 UPDATE: CervoMed (CRVO) - The Going Concern Flag Is Back Up
• 2026-10-30 UPDATE: CervoMed (CRVO) - The Peer-Reviewed Number Is Smaller 🔒 Paid
• 2026-10-12 UPDATE: CervoMed (CRVO) - The nfvPPA Signal Is a Whisper, Not a Shout 🔒 Paid
• 2026-09-29 UPDATE: CervoMed (CRVO) - The Speed Limit Comes Off 🔒 Paid
• 2026-08-08 UPDATE: CervoMed (CRVO) — The Going Concern Flag Just Came Down
• 2026-08-05 UPDATE: CervoMed (CRVO) — The UK Just Handed Them a Fast Lane 🔒 Paid
• 2026-07-14 UPDATE: CervoMed (CRVO) — The AAIC Receipts and the 80 mg BID Safety Read
• 2026-06-18 UPDATE: CervoMed (CRVO) — Stopgap #2, A 2042 Patent, and a +71% Tape 🔒 Paid
• 2026-06-15 UPDATE: CervoMed (CRVO) — Same Data, Louder Font
• 2026-06-10 UPDATE: CervoMed (CRVO) - The Bag Got Secured. Sort Of.
• 2026-05-16 UPDATE: CervoMed (CRVO) - The Q1 10-Q Confirms the Countdown
• 2026-04-27 UPDATE: CervoMed (CRVO) - The Brain Scans Just Got Randomized 🔒 Paid
• 2026-03-29 UPDATE: CervoMed (CRVO) – Global Regulatory Blessing and Biological Proof at Roth 🔒 Paid
• 2026-03-21 UPDATE: CervoMed (CRVO) – The 6-Month Warning and the Smoking Gun in Copenhagen 🔒 Paid
• 2026-03-14 UPDATE: CervoMed (CRVO) – Annual Report Drops 🔒 Paid
• 2026-03-07 UPDATE: CervoMed (CRVO) – The Bad Batch Fix is In... 🔒 Paid
• 2025-12-31 CervoMed (CRVO): Scientific Due Diligence for Neflamapimod

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (17 calls)

Every verdict Biotech Distilled has published on CervoMed, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2025-12-31 Watch CervoMed (CRVO): Scientific Due Diligence for Neflamapimod The science is plausible but the company must raise capital imminently; wait for the inevitable dilutive financing to reprice the stock before entering.
2. 2026-03-07 Watch UPDATE: CervoMed (CRVO) – The Bad Batch Fix is In... CMC update confirms the polymorph fix with hard PK data, but the dilution gap remains; wait for the financing to hit before entering.
3. 2026-03-14 Watch UPDATE: CervoMed (CRVO) – Annual Report Drops 10-K confirms tightening cash runway and a narrowing liver safety margin; wait for the financing and dilution before re-evaluating.
4. 2026-03-21 Watch UPDATE: CervoMed (CRVO) – The 6-Month Warning and the Smoking Gun in Copenhagen PK/PD data from Copenhagen proves the Bad Batch theory, but the 6-month cash runway makes a capital raise imminent; stay on the watch list until the dilution hits.
5. 2026-03-29 Watch UPDATE: CervoMed (CRVO) – Global Regulatory Blessing and Biological Proof at Roth Global regulatory alignment (FDA/EMA/MHRA) and MRI/PET biological proof strengthen the asset, but the financing gap remains the dominant constraint.
6. 2026-04-27 Watch UPDATE: CervoMed (CRVO) - The Brain Scans Just Got Randomized Blinded placebo-controlled MRI data strengthens the synaptic rescue thesis, but the dilution gap remains the binding constraint; the trigger is still the announced financing.
7. 2026-05-16 Watch UPDATE: CervoMed (CRVO) - The Q1 10-Q Confirms the Countdown Q1 10-Q confirms $12.9M cash and ~5 months of runway; deferred offering costs signal an imminent raise, but the trigger remains the announced financing.
8. 2026-06-10 Avoid UPDATE: CervoMed (CRVO) - The Bag Got Secured. Sort Of. The $10.5M stopgap PIPE was warrant-laden, insider-heavy, and far too small to fund Phase 3; the company formally pivoted to a partner-or-bust strategy, making the binary worse.
9. 2026-06-15 Avoid UPDATE: CervoMed (CRVO) — Same Data, Louder Font The H.C. Wainwright summit deck contains no new clinical data or partner announcement; the company remains partner-or-bust with the same cap table from June 10.
10. 2026-06-18 Avoid UPDATE: CervoMed (CRVO) — Stopgap #2, A 2042 Patent, and a +71% Tape A second $10M raise in eight days and a 2042 use patent improve the moat but confirm the company cannot self-fund Phase 3; chasing a 71% move into an active ATM is the inverse of the Sniper trade.
11. 2026-07-14 Avoid UPDATE: CervoMed (CRVO) — The AAIC Receipts and the 80 mg BID Safety Read AAIC data tightens the efficacy narrative and partially defuses the liver-tox concern, but no partner has signed and the equity remains partner-or-bust.
12. 2026-08-05 Avoid UPDATE: CervoMed (CRVO) — The UK Just Handed Them a Fast Lane The UK ILAP Innovation Passport improves the asset's commercial profile but is process, not evidence, and does not constitute a signed partner.
13. 2026-08-08 Watch UPDATE: CervoMed (CRVO) — The Going Concern Flag Just Came Down The Q2 10-Q removes the going-concern warning with $24.9M cash and runway through Q3 2027, satisfying the single precondition for upgrading off AVOID, though no partner has yet signed.
14. 2026-09-29 Watch UPDATE: CervoMed (CRVO) - The Speed Limit Comes Off FDA lifted the plasma exposure cap and a stable-crystal tablet reached Phase 1, improving the asset's sellability, but the Phase 3 remains contingent on a partner and the new 200 mg/day dose raises liver-tox questions.
15. 2026-10-12 Watch UPDATE: CervoMed (CRVO) - The nfvPPA Signal Is a Whisper, Not a Shout The nfvPPA 12-week NfL readout is directionally encouraging but statistically unproven and accompanied by a second liver discontinuation; the partner trigger remains unchanged.
16. 2026-10-30 Watch UPDATE: CervoMed (CRVO) - The Peer-Reviewed Number Is Smaller Peer-reviewed RewinD-LB data confirms the Bad Batch exposure-response story but the pure-DLB effect size is smaller (−0.70, CI touching zero); the partner trigger is unchanged.
17. 2026-11-07 Avoid UPDATE: CervoMed (CRVO) - The Going Concern Flag Is Back Up The Q3 10-Q reinstates the going-concern warning and discloses an investor lawsuit over the June raise, removing the sole condition that justified the August upgrade to Watch List.

• Avoid call · opened Jun 11, 2026 at $2.44 · closed Aug 10, 2026 (downgraded to WATCH from avoid) at $2.86 · +17.2% vs XBI +19.2%
• Avoid call · opened Nov 6, 2026 at $1.42 · 0.0% vs XBI 0.0% (Nov 6, 2026) · provisional

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (52)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 6, 202610-QQuarterly report→ BD update
• Oct 29, 2026ReleaseCervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)→ BD updateSummary on the 8-K
• Oct 29, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateCervoMed's full Phase 2b RewinD-LB placebo-controlled data hits peer review in *Alzheimer's Research & Therapy* today — the Bad Batch thesis now has a journal citation — but the stock has cratered 30% since the October 12 nfvPPA readout, and none of today's publications bring a partner any closer.BD extracted 1 program update from this document → CRVO pipeline
• Oct 14, 20268-KCurrent report: Reg FD disclosure
• Oct 13, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
• Oct 12, 2026ReleaseCervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Brea→ BD updateThe nfvPPA biomarker data the thesis has been waiting for landed today — NfL dropped where natural history says it should rise, but the n is small, the design is open-label, and the stock is down 22% on the session. Here's what the data actually means for the partner pitch.BD extracted 1 program update from this document → CRVO pipeline
• Oct 9, 20268-KCurrent report: Reg FD disclosure
• Sep 28, 2026ReleaseCervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit→ BD updateSummary on the 8-K
• Sep 28, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateCervoMed just announced a new 50 mg tablet formulation, a switch to 100 mg BID dosing, and — critically — FDA removal of the prior plasma exposure limit, delivering the most complete CMC and regulatory de-risking of neflamapimod since the Bad Batch fix began.BD extracted 1 program update from this document → CRVO pipeline
• Sep 22, 2026ReleaseCervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
• Sep 10, 2026ReleaseCervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT
• Sep 10, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
• Sep 8, 2026ReleaseCervoMed to Participate in September Investor Conferences
• Aug 10, 2026ReleaseCervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesBD extracted 1 program update from this document → CRVO pipeline
• Aug 10, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
• Aug 7, 202610-QQuarterly report
• Aug 5, 2026ReleaseCervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
• Aug 4, 2026ReleaseCervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
• Aug 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
• Jul 14, 2026ReleaseCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
• Jul 14, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
• Jul 10, 2026424B3Prospectus (resale / update)
• Jul 9, 2026ReleaseCervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
• Jul 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → CRVO pipeline
• Jul 6, 2026S-3Shelf registration
• Jul 6, 2026ReleaseCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026BD extracted 1 program update from this document → CRVO pipeline
• Jun 22, 2026ReleaseCervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
• Jun 22, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
• Jun 22, 20268-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1 EXHIBIT 99.1
• Jun 22, 2026424B5Prospectus supplement (offering)
• Jun 18, 2026ReleaseCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
• Jun 18, 2026ReleaseCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
• Jun 18, 20268-KCurrent report: other events
• Jun 15, 2026SCHEDULE 13D/A13D amendment
• Jun 15, 20268-KCurrent report: Reg FD disclosure
• Jun 12, 2026ReleaseCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
• Jun 10, 2026ReleaseCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
• Jun 10, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
• Jun 9, 20268-KCurrent report: shareholder vote
• May 18, 2026ReleaseCervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
• May 18, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
• May 15, 202610-QQuarterly report
• Apr 30, 2026DEF 14AProxy statement
• Apr 22, 2026ReleaseCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
• Apr 22, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
• Apr 7, 2026ReleaseCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
• Apr 7, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
• Mar 23, 20268-KCurrent report: Reg FD disclosure
• Mar 19, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
• Mar 17, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
• Mar 13, 202610-KAnnual report
• Mar 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1